
Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.
The American Journal of Managed Care
almost 26 years ago
Patient Preferences for Laboratory Test Results Notificationalmost 26 years ago
Determinants of Antidepressant Treatment Outcome